Webinars, Pharmaceutical
New Tools to Advance CNS Drug Delivery
17 Jul 2019
Currently, there are more than 30 companies involved in the development of therapeutics for delivery to the brain/central nervous system (CNS) via nasal deposition, for the treatment of disorders ranging from anxiety to Parkinson’s disease. This webinar focuses on the advantages of nasal powder formulations for CNS drug delivery referencing the use of a non-human primate (NHP) model to quantify nose-to-brain delivery of a model compound, sumatriptan. The reported study compared systemic and cerebral spinal fluid (CSF) drug concentrations of sumatriptan administered nasally from a dry powder drug delivery system, a liquid aerosol system and via subcutaneous delivery. A model was successfully developed to quantify CSF delivery indicating that the NHP model can be used to evaluate nasal delivery. Nasal powders were found to offer pharmacokinetic advantages relative to aqueous formulations. The potential for commercially successful CNS drug delivery via the nasal cavity is underlined with reference to a new esketamine nasal spray treatment for the treatment of major depressive disorder with imminent risk for suicide.
July 17, 2019
5:00 PM London / 12:00 PM New York
1 Hour
July 17 - July 17 2019 1:00 PM London / 8:00 AM New York
Presenter(s): Dr. Julie D. Suman Philip Kuehl
Presented By
Dr. Julie D. Suman
PhD, President, Next Breath, an Aptar Pharma Company
Julie holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). She is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Julie is a Past-Chair of the AAPS Inhalation Technology Focus Group. She is also a licensed Maryland pharmacist. Julie has published her research in peer-reviewed journals, has presented during podium sessions at international meetings such as the FDA Visiting Professor Lecture Series, and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001.
Philip Kuehl
PhD, Senior Scientist, Lovelace Biomedical
Philip Kuehl, Ph.D., is a Senior Scientist and Director of the Scientific Core Laboratories at Lovelace Biomedical. Dr. Kuehl is an expert in formulation by all routes, and is renowned for his contributions to pulmonary formulation and respiratory drug development. He has over 50 publications in drug development, drug delivery and formulation. He is a member of the International Society of Aerosols in Medicine and ad hoc reviewer of numerous journals. Dr. Kuehl received his B.A. in biochemistry from Hamline University in St. Paul, Minnesota and a Ph.D. in pharmaceutical sciences (minor in analytical chemistry) from the University of Arizona. Dr. Kuehl joined Lovelace in 2007.
Start a Project With Us
We Thrive on Transforming Ideas into Opportunities – Let Yours be Next.
